Zusammenfassung
Protein C ist das Proenzym einer Serinproteinase, wird von der Leber synthetisiert und Vitamin-K-abhängig mit γ-Carboxyglutamin-Gruppen (Gla) ausgestattet [23]. Die Aktivierung erfolgt durch Abspaltung eines aus 12 Aminosäuren bestehenden Aktivierungspeptids durch Thrombin und Proteasen ähnlicher Spezifität [24].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Bajzar L, Nesheim M, Morser J, Tracy PB (1998) Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem 273: 2792–2798
Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709
Bertina RM, Koeleman BP, Koster T et al. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64–67
Bouma BN, von dem Borne PA, Meijers JC (1998) Factor XI and protection of the fibrin clot against lysis — a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 80: 24–27
Briede J J, Tans G, Willems GM, Hemker HC, Lindhout T (2001) Regulation of platelet factor Va-dependent thrombin generation by activated protein C at the surface of collagen-adherent platelets. J Biol Chem 276: 7164–7168
Dahlback B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90: 1004–1008
De Cristofaro R, De Candia E, Landolfi R (1998) Effect of high- and low-molecular-weight heparins on thrombin-thrombomodulin interaction and protein C activation. Circulation 98: 1297–1301
de Fouw NJ, de Jong YF, Haverkate F, Bertina RM (1988) Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor — no evidence for a cofactor role of protein S. Thromb Haemost 60: 328–333
Elisen MG, von dem Borne PA, Bouma BN, Meijers JC (1998) Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood 91: 1542–1547
Esmon CT, Owen WG (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78: 2249–2252
Esmon CT, Xu J, Gu JM et al. (1999) Endothelial protein C receptor. Thromb Haemost 82: 251–258
Faust SN, Levin M, Harrison OB et al. (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408–416
Franco RF, Elion J, Tavella MH, Santos SE, Zago MA (1999) The prevalence of factor V Arg306→Thr (factor V Cambridge) and factor V Arg306→Gly mutations in different human populations. Thromb Haemost 81: 312–313
Gladson CL, Groncy P, Griffin JH (1987) Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency. Arch Dermatol 123:170la–1706a
Gu JM, Katsuura Y, Ferrell GL, Grammas P, Esmon CT (2001) Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood 95: 1687–1693
Healy AM, Hancock WW, Christie PD,Rayburn HB, Rosenberg RD (1998) Intravascular coagulation activation in a murine model of thrombomodulin deficiency: effects of lesion size, age, and hypoxia on fibrin deposition. Blood 92: 4188–4197
Hockin MF, Kalafatis M, Shatos M, Mann KG (1997) Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vase Biol 17: 2765–2775
Howard TE, Marusa M, Channell C, Duncan A (1997) A patient homozygous for a mutation in the prothrombin gene 3′-untranslated region associated with massive thrombosis. Blood Coagul Fibrinolysis 8: 316–319
Isermann B, Hendrickson SB, Zogg M et al. (2001) Endothelium-specifk loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 108: 537–546
Ishii H, Majerus PW (1985) Thrombomodulin is present in human plasma and urine. J Clin Invest 76: 2178–2181
Iwashima Y, Sato T, Watanabe K et al. (1990) Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 39: 983–988
Kalafatis M, Mann KG (1993) Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 268: 27246–27257
Kisiel W (1979) Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest 64: 761–769
Kisiel W, Ericsson LH, Davie EW (1976) Proteolytic activation of protein C from bovine plasma. Biochemistry 15: 4893–4900
Lindahl AK, Boffa MC, Abildgaard U (1993) Increased plasma thrombomodulin in cancer patients. Thromb Haemost 69: 112–114
Mosnier LO, Meijers JC, Bouma BN (2001) Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 85: 5–11
Neese LL, Pratt CW, Church FC (1994) Modulation of protein C inhibitor activity. Blood Coagul Fibrinolysis 5: 737–746
Nishioka J, Ning M, Hayashi T, Suzuki K (1998) Protein C inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesicles. J Biol Chem 273: 11281
O’Brien LM, Mastri M, Fay PJ (2000) Regulation of factor Villa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 95: 1714–1720
Ohlin AK, Morser J, Ohlin H (1996) Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. Thromb Res 82: 313–322
Petaja J, Fernandez JA, Gruber A, Griffin JH (1997) Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest 99: 2655–2663
Rappaport ES, Speights VO, Heibert B, Trowbridge A, Koops B, Montgomery RR, Marlar RA (1987) Protein C deficiency. South Med J 80: 240–242
Rezaie AR (2001) Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 276: 15567–15570
Shen L, He X, Dahlback B (1997) Synergistic cofactor function of factor V and protein S to activated protein C in the inactivation of the factor Villa - factor IXa complex — species specific interactions of components of the protein C anticoagulant system. Thromb Haemost 78: 1030–1036
Smirnov MD, Safa O, Esmon NL, Esmon CT (1999) Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 94: 3839–3846
Stewart RJ, Fredenburgh JC, Rischke JA, Bajzar L, Weitz JI (2000) Thrombin-activable fibrinolysis inhibitor attenuates DD(E)-mediated stimulation of plasminogen activation by reducing the affinity of DD(E) for tissue plasminogen activator. J Biol Chem 275: 36612–36620
Suzuki K, Stenflo J, Dahlback B, Teodorsson B (1983) Inactivation of human coagulation factor V by activated protein C. J Biol Chem 258: 1914–1920
Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 97: 1685–1688
Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S et al. (2001) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95: 1680–1686
van de Poel RH, Meijers JC, Bouma BN (2001) C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor Villa. Thromb Haemost 85: 761–775
van de Poel RH, Meijers JC, Rosing J, Tans G, Bouma BN (2000) C4b-binding protein protects coagulation factor Va from inactivation by activated protein C. Biochemistry 39: 14543–14548
Vincent JL (2001) Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology. Crit Care 5: S1–S5
Walker JB, Nesheim ME (2001) A kinetic analysis of the tissue plasminogen activator and DSPAa1 cofactor activities of untreated and TAFIa-treated soluble fibrin degradation products of varying size. J Biol Chem 276: 3138–3148
Weiler-Guettler H, Christie PD, Beeler DL et al. (1998) A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 101: 1983–1991
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dempfle, CE. (2002). Protein-C-Pathway. In: Martin, E., Nawroth, P. (eds) Fachübergreifende Aspekte der Hämostaseologie V. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-93394-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-93394-3_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-43350-7
Online ISBN: 978-3-642-93394-3
eBook Packages: Springer Book Archive